Results 31 to 40 of about 29,994,236 (203)

Cleavage and Polyadenylation Specificity Factor 6 Is Required for Efficient HIV-1 Latency Reversal. [PDF]

mBio, 2021
CPSF6 is a cellular factor that regulates cleavage and polyadenylation of mRNAs and participates in HIV-1 infection by facilitating targeting of preintegration complexes to the chromatin. Our observations reveal a second role of CPSF6 in the HIV-1 life cycle that involves regulation of viral transcription through controlling the stability of protein ...
Zheng Y, Schubert HL, Singh PK, Martins LJ, Engelman AN, D'Orso I, Hill CP, Planelles V.   +7 more
europepmc   +4 more sources

NSC95397 Is a Novel HIV-1 Latency-Reversing Agent

Viruses, 2023
The latent viral reservoir represents one of the major barriers to curing HIV-1. Focus on the “kick and kill” (also called “shock and kill”) approach, in which virus expression is reactivated, and then cells producing virus are selectively depleted, has led to the discovery of many latency-reversing agents (LRAs) that have furthered our understanding ...
Randilea Nichols Doyle, Vivian Yang, Yetunde I. Kayode, Robert Damoiseaux, Harry E. Taylor, Oliver I. Fregoso   +5 more
openaire   +6 more sources

Croton oligandrus Pierre & Hutch (Euphorbiaceae) Extracts and Isolated Compounds Reverse HIV-1 Latency [PDF]

Journal of Experimental Pharmacology
Chantal Emade Nkwelle,1,2 Smith B Babiaka,3,4 Clovis S Metuge,2,3 Kimberly Liang,5 Unique Stephens,5 Seraphine Nkie Esemu,1 David S Zuzga,5 Kristy Shuda McGuire,5 Luis J Montaner,5 Roland N Ndip,1 Ian Tietjen,5 Fidele Ntie-Kang2,3,6 1Department of ...
Emade Nkwelle C, Babiaka SB, Metuge CS, Liang K, Stephens U, Esemu SN, Zuzga DS, Shuda McGuire K, Montaner LJ, Ndip RN, Tietjen I, Ntie-Kang F   +11 more
doaj   +1 more source

Inhibitors of Signaling Pathways That Block Reversal of HIV-1 Latency [PDF]

Antimicrobial Agents and Chemotherapy, 2019
Signaling pathways play a key role in HIV-1 latency. In this study, we used the 24ST1NLESG cell line of HIV-1 latency to screen a library of structurally diverse, medicinally active, cell permeable kinase inhibitors, which target a wide range of signaling pathways, to identify inhibitors of HIV-1 latency reversal.
Benni, Vargas, Nicholas S, Giacobbi, Anwesha, Sanyal, Narasimhan J, Venkatachari, Feng, Han, Phalguni, Gupta, Nicolas, Sluis-Cremer   +6 more
openaire   +2 more sources

Human Immunodeficiency Virus-1 Latency Reversal via the Induction of Early Growth Response Protein 1 to Bypass Protein Kinase C Agonist-Associated Immune Activation

Frontiers in Microbiology, 2022
Human Immunodeficiency Virus-1 (HIV) remains a global health challenge due to the latent HIV reservoirs in people living with HIV (PLWH). Dormant yet replication competent HIV harbored in the resting CD4+ T cells cannot be purged by antiretroviral ...
Lilly M. Wong, Dajiang Li, Yuyang Tang, Gema Méndez-Lagares, George R. Thompson, Dennis J. Hartigan-O’Connor, Satya Dandekar, Guochun Jiang, Guochun Jiang   +8 more
doaj   +1 more source

Secreted factors induced by PKC modulators do not indirectly cause HIV latency reversal [PDF]

, 2023
HIV can establish a long-lived latent infection in cells harboring integrated non-expressing proviruses. Latency reversing agents (LRAs), including protein kinase C (PKC) modulators, can induce expression of latent HIV, thereby reducing the latent ...
Hourani, Rami, Marsden, Matthew D, Kim, Jocelyn T, Wender, Paul A, Ranjan, Alok, Zack, Jerome A, Moran, Jose A   +6 more
core   +1 more source

Moving Toward a Functional Cure for HIV-1

Infectious Diseases & Immunity, 2021
. Despite the recent success of suppressing human immunodeficiency virus 1 (HIV-1) replication in the peripheral blood with antiretroviral therapy, elimination of the provirus from infected cells remains challenging because the virus can integrate into ...
Wen Kang, Yongtao Sun, Haijuan Wang
doaj   +1 more source

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

PLOS Pathogens, 2015
Pharmacologically-induced activation of replication competent proviruses from latency in the presence of antiretroviral treatment (ART) has been proposed as a step towards curing HIV-1 infection. However, until now, approaches to reverse HIV-1 latency in humans have yielded mixed results.
Søgaard, OS, Graversen, ME, Leth, S, Olesen, R, Brinkmann, CR, Nissen, SK, Kjaer, AS, Schleimann, MH, Denton, PW, Hey-Cunningham, WJ, Koelsch, KK, Pantaleo, G, Krogsgaard, K, Sommerfelt, M, Fromentin, R, Chomont, N, Rasmussen, TA, Østergaard, L, Tolstrup, M   +18 more
openaire   +8 more sources

Reversal of HIV-1 latency with anti-microRNA inhibitors [PDF]

The International Journal of Biochemistry & Cell Biology, 2009
Human immunodeficiency virus type 1 (HIV-1) latency is achieved when host cells contain integrated proviral DNA but do not produce viral particles. The virus remains in resting CD4 T-lymphocytes, evading host immune surveillance and antiviral drugs. When resting cells are activated, infectious viral particles are produced.
openaire   +2 more sources

Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption [PDF]

Journal of Virology, 2017
ABSTRACT There is growing interest in utilizing antibody-dependent cellular cytotoxicity (ADCC) to eliminate infected cells following reactivation from HIV-1 latency. A potential barrier is that HIV-1-specific ADCC antibodies decline in patients on long-term antiretroviral therapy (ART) and may not be sufficient to eliminate ...
Lee, WS, Kristensen, AB, Rasmussen, TA, Tolstrup, M, Østergaard, L, Søgaard, OS, Wines, BD, Mark Hogarth, P, Reynaldi, A, Davenport, MP, Emery, S, Amin, J, Cooper, DA, Kan, VL, Fox, J, Gruell, H, Parsons, MS, Kent, SJ   +17 more
openaire   +6 more sources